View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Nov. 15 (HealthDay News) -- Vyvanse (lisdexamfetamine dimesylate) capsules have been approved by the U.S. Food and Drug Administration to treat attention deficit hyperactivity disorder (ADHD) among adolescents aged 13 to 17, maker Shire Pharmaceuticals said Monday.
The FDA previously approved the drug for ADHD in adults and children aged 6 years to 12 years, the British company said in a news release.
Vyvanse was evaluated in clinical trials involving 314 adolescents with ADHD. The most frequently reported side effects were decreased appetite, insomnia and weight loss. Results in adolescents were consistent with earlier findings in adults and children, Shire said.
Vyvanse is a controlled substance and should not be taken by people with heart disease, hardening of the arteries, moderate-to-severe high blood pressure, overactive thyroid, glaucoma, a history of drug abuse, or with a known sensitivity to stimulant medications, the company said.
To learn more about ADHD, visit the U.S. Centers for Disease Control and Prevention.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top